Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease

Cutis. 2023 Nov;112(5):E16-E17. doi: 10.12788/cutis.0899.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Eczema*
  • Eczema, Dyshidrotic* / complications
  • Humans
  • Treatment Outcome

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized